ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

MANAGEMENT REPORT

Management's Responsibility for Financial Reporting

The accompanying financial statements have been prepared by Mackenzie Financial Corporation, as Manager of Mackenzie Ivy International Fund (the "Fund"). The Manager is responsible for the integrity, objectivity and reliability of the data presented. This responsibility includes selecting appropriate accounting principles and making judgments and estimates consistent with IFRS Accounting Standards. The Manager is also responsible for the development of internal controls over the financial reporting process, which are designed to provide reasonable assurance that relevant and reliable financial information is produced.

The Board of Directors (the "Board") of Mackenzie Financial Corporation is responsible for reviewing and approving the financial statements and overseeing the Manager's performance of its financial reporting responsibilities. The Board meets regularly with the Manager, internal auditors and external auditors to discuss internal controls over the financial reporting process, auditing matters and financial reporting issues.

KPMG LLP is the external auditor of the Fund. It is appointed by the Board. The external auditor has audited the financial statements in accordance with Canadian generally accepted auditing standards to enable it to express to the securityholders its opinion on the financial statements. Its report is set out below.

On behalf of Mackenzie Financial Corporation, Manager of the Fund

Signed "Luke Gould"

Luke Gould
President and Chief Executive Officer
Mackenzie Financial Corporation
June 4, 2025

Signed "Terry Rountes"

Terry Rountes Chief Financial Officer, Funds Mackenzie Financial Corporation

INDEPENDENT AUDITOR'S REPORT

To the Securityholders of Mackenzie Ivy International Fund (the "Fund")

Opinion

We have audited the financial statements of the Fund, which comprise:

- the statements of financial position as at March 31, 2025 and March 31, 2024
- the statements of comprehensive income for the periods then ended as indicated in note 1
- the statements of changes in financial position for the periods then ended as indicated in note 1
- . the statements of cash flows for the periods then ended as indicated in note 1 and
- notes to the financial statements, including a summary of material accounting policies (Hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Fund as at March 31, 2025 and March 31, 2024, and its financial performance and cash flows for the periods then ended as indicated in note 1 in accordance with IFRS Accounting Standards.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our auditor's report.

We are independent of the Fund in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

INDEPENDENT AUDITOR'S REPORT (cont'd)

Other Information

Management is responsible for the other information. Other information comprises:

- the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions.

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information included in the Annual Management Report of Fund Performance of the Fund filed with the relevant Canadian Securities Commissions as at the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditor's report.

We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRS Accounting Standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Fund's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Fund or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the financial reporting process of the Fund.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.
 - The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the internal control.
- . Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Fund to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Chartered Professional Accountants, Licensed Public Accountants Toronto, Canada

June 4, 2025

KPMG LLP

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

STATEMENTS OF FINANCIAL POSITION

at March 31 (in \$ 000 except per security amounts)

	2025 \$	2024 \$
ASSETS		
Current assets		
Investments at fair value	68,176	67,530
Cash and cash equivalents	3,115	2,897
Dividends receivable	118	106
Accounts receivable for investments sold	_	698
Accounts receivable for securities issued	5	59
Due from manager	32	-
Derivative assets	32	411
Total assets	71,478	71,701
LIABILITIES		
Current liabilities		
Accounts payable for investments purchased	7	214
Accounts payable for securities redeemed	37	85
Due to manager	6	6
Derivative liabilities	858	62
Total liabilities	908	367
Net assets attributable to securityholders	70,570	71,334

	Net assets at	tributable to s	securityholders	s (note 3)
	per secu	ırity	per sei	ries
	2025	2024	2025	2024
Series A	21.18	19.12	10,166	10,845
Series AR	13.08	11.82	735	598
Series D	15.20	13.60	2,290	2,288
Series F	8.78	7.86	10,003	10,578
Series F5	14.54	13.64	24	22
Series F8	12.40	11.98	29	19
Series FB	13.59	12.17	13	95
Series FB5	15.18	14.24	1	1
Series I	9.39	8.42	469	428
Series 0	8.91	7.95	1,437	1,354
Series PW	15.74	14.16	9,255	9,976
Series PWFB	13.80	12.35	77	27
Series PWFB5	15.17	14.22	2	1
Series PWR	13.13	11.81	537	398
Series PWT5	14.63	13.79	38	34
Series PWT8	12.24	11.90	1	1
Series PWX	15.47	13.81	48	38
Series PWX8	12.49	12.03	2	1
Series R	=	12.68	-	129
Series S	23.33	20.83	34,512	33,628
Series T5	14.08	13.28	1	_
Series T8	11.99	11.70	3	1
Series LB	14.08	12.73	79	77
Series LF	11.03	9.87	64	44
Series LW	13.08	11.79	784	751
			70,570	71,334

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

STATEMENTS OF COMPREHENSIVE INCOME

for the periods ended March 31 (in \$ 000 except per security amounts)

	2025 \$	2024 \$
Income	Ψ	Ψ
Dividends	1,311	1.741
Interest income for distribution purposes	17	24
Other changes in fair value of investments and other net assets		
Net realized gain (loss)	3,916	(2,597)
Net unrealized gain (loss)	3,980	7,547
Securities lending income	5	5
Total income (loss)	9,229	6,720
Expenses (note 6)		
Management fees	587	626
Management fee rebates	_	(4)
Administration fees	84	89
Interest charges	5	13
Commissions and other portfolio transaction costs	94	95
Independent Review Committee fees	=	-
Other	1	2
Expenses before amounts absorbed by Manager	771	821
Expenses absorbed by Manager	_	
Net expenses	771	821
Increase (decrease) in net assets attributable to		
securityholders from operations before tax	8,458	5,899
Foreign withholding tax expense (recovery)	130	206
Foreign income tax expense (recovery)		
Increase (decrease) in net assets attributable to securityholders from operations	8,328	5,693

	to securit	to securityholders from operations (note 3)					
	per secu	rity	per seri	es			
	2025	2024	2025	2024			
Series A	2.09	1.10	1,080	678			
Series AR	1.25	0.74	67	36			
Series D	1.65	1.80	264	243			
Series F	0.98	0.55	1,178	919			
Series F5	1.65	1.06	2	2			
Series F8	1.39	1.18	3	-			
Series FB	1.60	0.89	9	11			
Series FB5	1.68	1.08	-	-			
Series I	0.98	0.60	48	30			
Series 0	1.06	0.68	171	115			
Series PW	1.57	0.83	1,006	652			
Series PWFB	1.53	0.75	8	3			
Series PWFB5	1.72	1.10	1	-			
Series PWR	1.23	0.76	42	27			
Series PWT5	1.51	0.88	4	3			
Series PWT8	1.26	0.83	_	-			
Series PWX	1.93	1.04	7	3			
Series PWX8	1.57	1.08	1	_			
Series R	(0.47)	1.05	(4)	10			
Series S	2.82	1.73	4,347	2,908			
Series T5	1.45	(0.47)	1	(1)			
Series T8	0.61	0.76	_	-			
Series LB	1.34	0.73	8	4			
Series LF	1.34	0.85	8	3			
Series LW	1.27	0.60	77	47			
			8,328	5,693			

Increase (decrease) in net assets attributable

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

STATEMENTS OF CHANGES IN FINANCIAL POSITION

for the periods ended March 31 (in \$ 000 except per security amounts)

	Tota	al	Series	Series A		AR	Series	s D	Series F	
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	71,334	78,210	10,845	11,966	598	507	2,288	902	10,578	14,674
Increase (decrease) in net assets from operations	8,328	5,693	1,080	678	67	36	264	243	1,178	919
Distributions paid to securityholders:										
Investment income	(540)	(779)	_	-	_	-	(7)	(14)	(54)	(109)
Capital gains	_	-	_	-	_	-	_	-	_	-
Return of capital	(5)	(4)	_	-	_	-	_	-	_	-
Management fee rebates	_	(4)	_	-	_	-	_	-	_	-
Total distributions paid to securityholders	(545)	(787)	-	-	_	-	(7)	(14)	(54)	(109)
Security transactions:										
Proceeds from securities issued	4,884	5,785	856	661	259	89	206	1,352	880	1,711
Reinvested distributions	532	756	_	-	_	-	7	14	41	80
Payments on redemption of securities	(13,963)	(18,323)	(2,615)	(2,460)	(189)	(34)	(468)	(209)	(2,620)	(6,697)
Total security transactions	(8,547)	(11,782)	(1,759)	(1,799)	70	55	(255)	1,157	(1,699)	(4,906)
Increase (decrease) in net assets attributable to securityholders	(764)	(6,876)	(679)	(1,121)	137	91	2	1,386	(575)	(4,096)
End of period	70,570	71,334	10,166	10,845	735	598	2,290	2,288	10,003	10,578
Increase (decrease) in fund securities (in thousands) (note 7):			Securi	ties	Securi	ties	Securi	ties	Securi	ties
Securities outstanding – beginning of period			567	667	51	46	168	71	1,346	2,001
Issued			42	37	20	8	15	109	103	235
Reinvested distributions			_	-	_	-	_	1	5	11
Redeemed			(129)	(137)	(15)	(3)	(32)	(13)	(315)	(901)
Securities outstanding – end of period			480	567	56	51	151	168	1,139	1,346

	Series	s F5	Series	F8	Series	FB	Series	FB5	Serie	s I
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	22	20	19	11	95	86	1	1	428	420
Increase (decrease) in net assets from operations	2	2	3	_	9	11	_	_	48	30
Distributions paid to securityholders:										
Investment income	_	-	_	-	_	(1)	_	-	_	(2)
Capital gains	_	-	_	-	_	-	_	-	_	-
Return of capital	(1)	(1)	(2)	(1)	_	-	_	-	_	-
Management fee rebates		_		_		_		_		_
Total distributions paid to securityholders	(1)	(1)	(2)	(1)	_	(1)	_	_	_	(2)
Security transactions:										
Proceeds from securities issued	_	-	9	8	8	4	_	-	2	-
Reinvested distributions	1	1	2	1	_	-	_	-	_	2
Payments on redemption of securities		_	(2)	_	(99)	(5)		_	(9)	(22)
Total security transactions	1	1	9	9	(91)	(1)	_	_	(7)	(20)
Increase (decrease) in net assets attributable to securityholders	2	2	10	8	(82)	9	_	_	41	8
End of period	24	22	29	19	13	95	1	1	469	428
Increase (decrease) in fund securities (in thousands) (note 7):	Secur	ities	Securi	ties	Securi	ties	Secur	ities	Securi	ties
Securities outstanding – beginning of period	2	2	2	1	8	8	_	-	51	53
Issued	_	_	_	1	1	_	_	_	_	_
Redeemed	_	_	_	_	_	_	_	_	_	_
Transferred on reorganization	_	_	_	_	(8)	_	_	_	(1)	(2)
Securities outstanding – end of period	2	2	2	2	1	8	_	_	50	51

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

for the periods ended March 31 (in \$ 000 except per security amounts)

	Serie	s 0	Series	PW	Series PWFB		Series P	WFB5	Series F	PWR
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	1,354	1,266	9,976	12,256	27	44	1	1	398	398
Increase (decrease) in net assets from operations	171	115	1,006	652	8	3	1	-	42	27
Distributions paid to securityholders:										
Investment income	(19)	(25)	_	-	_	-	_	-	_	-
Capital gains	_	-	_	-	_	-	_	-	_	-
Return of capital	_	-	_	-	_	-	_	-	_	-
Management fee rebates		_		(4)						
Total distributions paid to securityholders	(19)	(25)		(4)						
Security transactions:										
Proceeds from securities issued	3	5	883	736	42	1	_	-	144	99
Reinvested distributions	19	25	_	3	_	-	_	-	_	-
Payments on redemption of securities	(91)	(32)	(2,610)	(3,667)		(21)			(47)	(126)
Total security transactions	(69)	(2)	(1,727)	(2,928)	42	(20)			97	(27)
Increase (decrease) in net assets attributable to securityholders	83	88	(721)	(2,280)	50	(17)	1		139	_
End of period	1,437	1,354	9,255	9,976	77	27	2	1	537	398
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Securi	ties	Securi	ties	Securi	ties
Securities outstanding – beginning of period	170	171	704	926	2	4	-	-	34	36
Issued	_	-	58	54	4	-	_	-	11	9
Reinvested distributions	2	3	-	-	_	-	_	-	-	-
Redeemed	(11)	(4)	(174)	(276)		(2)			(4)	(11)
Securities outstanding – end of period	161	170	588	704	6	2	_		41	34

	Series	PWT5	Series I	PWT8	Series F	wx	Series I	PWX8	Series	s R
	2025	2024	2025	2024	2025	2024	2025	2024	2025	2024
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS										
Beginning of period	34	41	1	1	38	50	1	1	129	108
Increase (decrease) in net assets from operations	4	3	_	-	7	3	1	-	(4)	10
Distributions paid to securityholders:										
Investment income	_	_	_	_	(1)	(1)	_	_	_	(3)
Capital gains	_	_	_	_	_	_	_	_	_	_
Return of capital	(2)	(2)	_	_	_	_	_	_	_	_
Management fee rebates	_	_	_	_	_	_	_	_	_	_
Total distributions paid to securityholders	(2)	(2)	_	_	(1)	(1)	_	_	_	(3)
Security transactions:										
Proceeds from securities issued	_	_	_	_	4	_	_	_	_	32
Reinvested distributions	2	2	_	_	1	1	_	_	_	3
Payments on redemption of securities	_	(10)	_	_	(1)	(15)	_	_	(125)	(21)
Total security transactions	2	(8)	_	_	4	(14)	_	_	(125)	14
Increase (decrease) in net assets attributable to securityholders	4	(7)	_	_	10	(12)	1	_	(129)	21
End of period	38	34	1	1	48	38	2	1	_	129
Increase (decrease) in fund securities (in thousands) (note 7):	Secu	rities	Secur	ities	Securit	ies	Secur	ities	Securi	ties
Securities outstanding – beginning of period	2	3	_	_	3	4	_	_	10	9
Issued	1	_	_	_	_	_	_	_	_	3
Reinvested distributions	_	_	_	_	_	_	_	_	_	_
Redeemed		(1)		_		(1)		_	(10)	(2)
Securities outstanding – end of period	3	2	_	_	3	3	_	_	_	10

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

STATEMENTS OF CHANGES IN FINANCIAL POSITION (cont'd)

for the periods ended March 31 (in \$ 000 except per security amounts)

	Series	S	Series	T5	Series T8		
	2025	2024	2025	2024	2025	2024	
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS							
Beginning of period	33,628	34,335	_	22	1	1	
Increase (decrease) in net assets from operations	4,347	2,908	1	(1)	_	_	
Distributions paid to securityholders:							
Investment income	(459)	(624)	_	-	_	-	
Capital gains	-	-	_	-	_	-	
Return of capital	_	-	_	-	_	-	
Management fee rebates		_		_			
Total distributions paid to securityholders	(459)	(624)		_			
Security transactions:							
Proceeds from securities issued	1,485	1,071	_	-	2	-	
Reinvested distributions	459	624	_	-	_	-	
Payments on redemption of securities	(4,948)	(4,686)		(21)			
Total security transactions	(3,004)	(2,991)		(21)	2		
Increase (decrease) in net assets attributable to securityholders	884	(707)	1	(22)	2		
End of period	34,512	33,628	1_		3	1_	
Increase (decrease) in fund securities (in thousands) (note 7):	Securi	ties	Securi	ties	Secur	ities	
Securities outstanding – beginning of period	1,614	1,767	_	2	_	_	
Issued	65	54	_	_	_	_	
Reinvested distributions	20	32	-	-	_	_	
Redeemed	(220)	(239)		(2)			
Securities outstanding – end of period	1,479	1,614		_			

	Series	LB	Series	LF	Series	LW
	2025	2024	2025	2024	2025	2024
NET ASSETS ATTRIBUTABLE TO SECURITYHOLDERS						
Beginning of period	77	83	44	26	751	990
Increase (decrease) in net assets from operations	8	4	8	3	77	47
Distributions paid to securityholders:						
Investment income	_	-	_	-	_	-
Capital gains	_	-	_	-	_	-
Return of capital	_	-	_	-	_	-
Management fee rebates						
Total distributions paid to securityholders						
Security transactions:						
Proceeds from securities issued	5	-	18	15	78	1
Reinvested distributions	_	-	_	-	_	-
Payments on redemption of securities	(11)	(10)	(6)		(122)	(287)
Total security transactions	(6)	(10)	12	15	(44)	(286)
Increase (decrease) in net assets attributable to securityholders	2	(6)	20	18	33	(239)
End of period	79	77	64	44	784	751
Increase (decrease) in fund securities (in thousands) (note 7):	Secur	ties	Securi	ties	Securi	ties
Securities outstanding – beginning of period	6	7	4	3	64	90
Issued	_	-	3	1	6	-
Reinvested distributions	-	-	_	-	_	-
Redeemed		(1)	(1)		(10)	(26)
Securities outstanding – end of period	6_	6	6	4	60	64

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

STATEMENTS OF CASH FLOWS

for the periods ended March 31 (in \$ 000)

Cash flows from operating activities Net increase (decrease) in net assets attributable to securityholders from operations Adjustments for: Net realized loss (gain) on investments Change in net unrealized loss (gain) on investments Proceeds from sale and maturity of investments Proceeds from sale and maturity of investments Cash glock in accounts receivable and other assets Ret cash provided by (used in) operating activities Cash flows from financing activities Proceeds from securities issued A,535 5,174 Payments on redemption of securities Proceeds from securities issued 3,535 5,174 Payments on redemption of securities (12,608) (17,717) Distributions paid net of reinvestments (13) (31) Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 202 (1,899) Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 1,299 1,741 Interest paid		2025 \$	2024 \$
securityholders from operations Adjustments for: Net realized loss (gain) on investments Change in net unrealized loss (gain) on investments Change in net unrealized loss (gain) on investments Change in net unrealized loss (gain) on investments Proceeds from sale and maturity of investments Class (decrease in accounts receivable and other assets Increase (decrease) in accounts payable and other liabilities Ant cash provided by (used in) operating activities Proceeds from securities issued Proceeds from securities (12,608) Proceeds from securities (13) Pet cash provided by (used in) financing activities Proceeds from securities Proceeds from securities (12,608) Proceeds from securities issued Payments on redemption of securities Proceeds from securities (12,608) Proceeds from securities issued Proceeds from securities (12,608) Proceeds from securities (12,608) Proceeds from securities issued Proceeds from securities (12,608)	Cash flows from operating activities		
Net realized loss (gain) on investments Change in net unrealized loss (gain) on investments Change in net unrealized loss (gain) on investments (16,630) Proceeds from sale and maturity of investments Proceeds from sale and maturity of investments 25,781 30,907 (Increase) decrease in accounts receivable and other assets (44) 1 Increase (decrease) in accounts payable and other liabilities - 4 Net cash provided by (used in) operating activities Proceeds from securities issued 3,535 5,174 Payments on redemption of securities Proceeds from securities issued 3,535 5,174 Payments on redemption of securities (12,608) Postributions paid net of reinvestments (13) Ret cash provided by (used in) financing activities Net increase (decrease) in cash and cash equivalents (9,086) Proceeds from securities Proceeds from securities (12,608) Proceeds from securities issued 3,535 5,174 Payments on redemption of securities (13) Pet cash provided by (used in) financing activities (9,086) Proceeds from securities Proceeds from securities issued 3,115 Pet cash and cash equivalents at beginning of period 2,897 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 16 Post increase (decrease) in cash and cash equivalents 17 Post increase (decrease) in cash and cash equivalents 18 Post increase (decrease) in cash and cash equivalents 19 Post increase (decrease) in cash and cash equivalents 10 Post increase (decrease) in cash and cash equivalents 10 Post increase (decrease) in cash and cash equivalents 10 Post increase (decrease) in cas	securityholders from operations	8,328	5,693
Change in net unrealized loss (gain) on investments(3,980)(7,547)Purchase of investments(16,630)(20,436)Proceeds from sale and maturity of investments25,78130,907(Increase) decrease in accounts receivable and other assets(44)1Increase (decrease) in accounts payable and other liabilities-4Net cash provided by (used in) operating activities9,28810,675Cash flows from financing activities9,28810,675Proceeds from securities issued3,5355,174Payments on redemption of securities(12,608)(17,717)Distributions paid net of reinvestments(13)(31)Net cash provided by (used in) financing activities(9,086)(12,574)Net increase (decrease) in cash and cash equivalents202(1,899)Cash and cash equivalents at beginning of period2,8974,819Effect of exchange rate fluctuations on cash and cash equivalents16(23)Cash and cash equivalents at end of period3,1152,897Cash and cash equivalents at end of period3,1152,897Cash equivalentsCash and cash equivalents at end of period3,1152,897Supplementary disclosures on cash flow from operating activities:1,2991,741Dividends received1,2991,741Foreign taxes paid130206Interest received1724	•	(4 167)	2.053
Purchase of investments Proceeds from sale and maturity of investments Proceeds in accounts receivable and other assets Proceeds (decrease) in accounts payable and other liabilities Proceeds from financing activities Proceeds from securities issued Proceeds from securities Proceeds from secu	•		
Proceeds from sale and maturity of investments (Increase) decrease in accounts receivable and other assets (Increase) decrease in accounts payable and other liabilities Increase (decrease) in accounts payable and other liabilities Proceeds from financing activities Proceeds from securities issued Proceeds from securities iss			
(Increase) decrease in accounts receivable and other assets (44) 1 Increase (decrease) in accounts payable and other liabilities — 4 Net cash provided by (used in) operating activities 9,288 10,675 Cash flows from financing activities 3,535 5,174 Proceeds from securities issued 3,535 5,174 Payments on redemption of securities (12,608) (17,717) Distributions paid net of reinvestments (13) (31) Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents — — Cash equivalents — — Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24	. a. onaco or mirodimento		
Increase (decrease) in accounts payable and other liabilities — 4 Net cash provided by (used in) operating activities 9,288 10,675 Cash flows from financing activities Proceeds from securities issued 3,535 5,174 Payments on redemption of securities (12,608) (17,717) Distributions paid net of reinvestments (13) (31) Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash 3,115 2,897 Cash equivalents — — Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24			•
Net cash provided by (used in) operating activities Cash flows from financing activities Proceeds from securities issued 3,535 5,174 Payments on redemption of securities (12,608) (17,717) Distributions paid net of reinvestments (13) (31) Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash Cash 3,115 2,897 Cash equivalents Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24	Increase (decrease) in accounts payable and other liabilities	_	4
Cash flows from financing activities Proceeds from securities issued 3,535 5,174 Payments on redemption of securities (12,608) (17,717) Distributions paid net of reinvestments (13) (31) Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash 3,115 2,897 Cash 3,115 2,897 Cash equivalents — — Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24		9,288	10,675
Proceeds from securities issued 3,535 5,174 Payments on redemption of securities (12,608) (17,717) Distributions paid net of reinvestments (13) (31) Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents — — Cash equivalents — — Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: — — Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24		•	
Payments on redemption of securities (12,608) (17,717) Distributions paid net of reinvestments (13) (31) Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents - - - Cash equivalents - - - Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: - - Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24	Cash flows from financing activities		
Distributions paid net of reinvestments (13) (31) Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents - - Cash equivalents - - Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24	Proceeds from securities issued	3,535	5,174
Net cash provided by (used in) financing activities (9,086) (12,574) Net increase (decrease) in cash and cash equivalents 202 (1,899) Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents - - Cash equivalents - - Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24	Payments on redemption of securities	(12,608)	(17,717)
Net increase (decrease) in cash and cash equivalents202(1,899)Cash and cash equivalents at beginning of period2,8974,819Effect of exchange rate fluctuations on cash and cash equivalents16(23)Cash and cash equivalents at end of period3,1152,897Cash3,1152,897Cash equivalentsCash and cash equivalents at end of period3,1152,897Supplementary disclosures on cash flow from operating activities:Dividends received1,2991,741Foreign taxes paid130206Interest received1724	Distributions paid net of reinvestments	(13)	(31)
Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents - - Cash equivalents - - Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: 1,299 1,741 Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24	Net cash provided by (used in) financing activities	(9,086)	(12,574)
Cash and cash equivalents at beginning of period 2,897 4,819 Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash equivalents - - Cash equivalents - - Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: 1,299 1,741 Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24			
Effect of exchange rate fluctuations on cash and cash equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash 3,115 2,897 Cash equivalents - - Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: 1,299 1,741 Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24			
equivalents 16 (23) Cash and cash equivalents at end of period 3,115 2,897 Cash 3,115 2,897 Cash equivalents - - Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24		2,897	4,819
Cash and cash equivalents at end of period 3,115 2,897 Cash 3,115 2,897 Cash equivalents — — Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24			()
Cash 3,115 2,897 Cash equivalents — — Cash and cash equivalents at end of period 3,115 2,897 Supplementary disclosures on cash flow from operating activities: Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24	- ·		
Cash equivalentsCash and cash equivalents at end of period3,1152,897Supplementary disclosures on cash flow from operating activities:Dividends received1,2991,741Foreign taxes paid130206Interest received1724	Cash and cash equivalents at end of period	3,115	2,897
Cash equivalentsCash and cash equivalents at end of period3,1152,897Supplementary disclosures on cash flow from operating activities:Dividends received1,2991,741Foreign taxes paid130206Interest received1724	Oark	2 115	2 207
Cash and cash equivalents at end of period3,1152,897Supplementary disclosures on cash flow from operating activities:Dividends received1,2991,741Foreign taxes paid130206Interest received1724		3,115	2,897
Supplementary disclosures on cash flow from operating activities: Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24		2 115	2 907
activities: Dividends received 1,299 1,741 Foreign taxes paid 130 206 Interest received 17 24	cash and cash equivalents at end of period	3,113	2,037
Foreign taxes paid 130 206 Interest received 17 24			
Foreign taxes paid 130 206 Interest received 17 24	Dividends received	1,299	1,741
Interest received 17 24		•	,
Interest paid 5 13	=	17	24
	Interest paid	5	<u>1</u> 3

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

SCHEDULE OF INVESTMENTS

as at March 31, 2025

			Par Value/ Number of	Average Cost	Fai Valu
Investment Name	Country	Sector	Shares/Units	(\$ 000)	(\$ 000
EQUITIES					
Admiral Group PLC	United Kingdom	Financials	46,609	1,682	2,47
Adyen NV	Netherlands	Financials	451	928	99
Ajinomoto Co. Inc.	Japan	Consumer Staples	49,200	1,329	1,40
Assa Abloy AB B	Sweden	Industrials	54,248	2,002	2,34
Auto Trader Group PLC	United Kingdom	Communication Services	72,840	726	1,01
Brambles Ltd.	Australia	Industrials	141,796	1,445	2,56
Brookfield Corp. Class A	Canada	Financials	31,750	1,221	2,39
Coloplast AS	Denmark	Health Care	8,300	1,273	1,25
	United Kingdom				
Compass Group PLC	· ·	Consumer Discretionary	58,263	1,558	2,76
Daikin Industries Ltd.	Japan	Industrials	9,400	1,551	1,46
De'Longhi SpA	Italy	Consumer Discretionary	21,086	682	1,00
Deutsche Boerse AG	Germany	Financials	6,392	1,685	2,71
Dollarama Inc.	Canada	Consumer Discretionary	7,200	343	1,10
Experian PLC	United Kingdom	Industrials	18,273	1,007	1,2
Greggs PLC	United Kingdom	Consumer Discretionary	22,234	1,051	7:
Halma PLC	United Kingdom	Information Technology	54,204	1,929	2,60
Howden Joinery Group PLC	United Kingdom	Industrials	65,014	610	87
Hoya Corp.	Japan	Health Care	8,700	1,402	1,4
InterContinental Hotels Group PLC	United Kingdom	Consumer Discretionary	9,300	1,624	1,44
Kone OYJ B	Finland	Industrials	13,526	836	1,0
L'Oreal SA	France	Consumer Staples	3,408	1,662	1,82
LVMH Moet Hennessy Louis Vuitton SE	France	Consumer Discretionary	1,600	1,486	1,4
Merck KGaA	Germany	Health Care	8,500	1,936	1,6
Murata Manufacturing Co. Ltd.	-				7(
	Japan	Information Technology	34,200	1,017	
Namco Bandai Holdings Inc.	Japan	Consumer Discretionary	15,000	422	72
Nestle SA Reg.	Switzerland	Consumer Staples	12,875	1,847	1,87
Nomura Research Institute Ltd.	Japan	Information Technology	29,700	1,098	1,38
Novo Nordisk AS B	Denmark	Health Care	8,430	1,083	84
Novonesis B	Denmark	Materials	15,500	1,036	1,30
Olympus Corp.	Japan	Health Care	46,800	1,074	88
Pan Pacific International Holdings Corp.	Japan	Consumer Discretionary	44,100	1,429	1,73
Partners Group Holding AG	Switzerland	Financials	475	610	97
Reckitt Benckiser Group PLC	United Kingdom	Consumer Staples	28,700	3,079	2,79
RELX PLC	United Kingdom	Industrials	21,392	747	1,54
Roche Holding AG Genusscheine	Switzerland	Health Care	5,450	2,417	2,57
Samsung Electronics Co. Ltd.	South Korea	Information Technology	31,000	1,905	1,76
SAP AG	Germany	Information Technology	2,724	487	1,04
Scout24 AG	-	Communication Services	7,755	651	1,10
	Germany				6
Seven & i Holdings Co. Ltd.	Japan Australia	Consumer Staples	29,900	523	
Sonic Healthcare Ltd.	Australia	Health Care	50,000	1,283	1,16
Spirax-Sarco Engineering PLC	United Kingdom	Industrials	8,855	1,047	1,0
Taiwan Semiconductor Manufacturing Co. Ltd.	Taiwan	Information Technology	35,200	528	1,4
Tencent Holdings Ltd.	China	Communication Services	10,800	763	9
Terumo Corp.	Japan	Health Care	75,300	1,585	2,0
Unicharm Corp.	Japan	Consumer Staples	73,800	1,139	8
Wolters Kluwer NV	Netherlands	Industrials	4,200	625	93
Total equities				56,363	68,1
Transaction costs				(132)	
Total investments				56,231	68,1
Derivative instruments					
(see schedule of derivative instruments)					(8)
Cash and cash equivalents					3,1
Other assets less liabilities					1
Net assets attributable to securityholders					70,5

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

SUMMARY OF INVESTMENT PORTFOLIO

MARCH 31, 2025

MARCH 31, 2024

PORTFOLIO ALLOCATION	% OF NAV	PORTFOLIO ALLOCATION	% OF NAV
Equities	96.6	Equities	94.7
Cash and cash equivalents	4.4	Cash and cash equivalents	4.1
Other assets (liabilities)	(1.0)	Other assets (liabilities)	1.2
REGIONAL ALLOCATION	% OF NAV	REGIONAL ALLOCATION	% OF NAV
United Kingdom	26.3	United Kingdom	24.9
Japan	18.8	Japan	17.0
Germany	9.3	Switzerland	10.3
Switzerland	7.7	Germany	8.7
Australia	5.3	Australia	7.1
Canada	5.0	Denmark	5.8
Denmark	4.8	Canada	4.8
France	4.6	Cash and cash equivalents	4.1
Cash and cash equivalents	4.4	Netherlands	3.3
Sweden	3.3	Taiwan	2.8
Netherlands	2.7	South Korea	2.6
South Korea	2.5	Sweden	2.2
Taiwan	2.0	Finland	2.0
Finland	1.5	China	1.8
Italy	1.4	Italy	1.4
Other	1.4	Other assets (liabilities)	1.2
Other assets (liabilities)	(1.0)		
SECTOR ALLOCATION	% OF NAV	SECTOR ALLOCATION	% OF NAV
Industrials	18.5	Consumer staples	17.6
Health care	16.8	Industrials	16.1
Consumer discretionary	15.5	Health care	15.2
Financials	13.5	Information technology	14.9
Consumer staples	13.3	Financials	11.4
Information technology	12.7	Consumer discretionary	11.0
Communication services	4.5	Communication services	4.3
Cash and cash equivalents	4.4	Materials	4.2
Materials	1.8	Cash and cash equivalents	4.1
Other assets (liabilities)	(1.0)	Other assets (liabilities)	1.2

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

SCHEDULE OF DERIVATIVE INSTRUMENTS

as at March 31, 2025

Counterparty Credit Rating	Curreno Received	cy to be d (\$ 000)	Currency Delivered		Settlement Date	Contract Cost (\$ 000)	Current Fair Value (\$ 000)	Unrealized Gains (\$ 000)	Unrealize Losses (\$ 000)
A	3,787	CAD	(2,390)	CHF	Apr. 9, 2025	(3,787)	(3,890)	=	(10
Α	96	CAD	(60)	CHF	Apr. 9, 2025	(96)	(98)	_	(
Α	205	CAD	(130)	CHF	Apr. 9, 2025	(205)	(212)	=	(
Α	202	CHF	(325)	CAD	Apr. 9, 2025	325	328	3	
Α	295	CAD	(1,597)	HKD	Apr. 9, 2025	(295)	(296)	_	
Α	20	CAD	(110)	HKD	Apr. 9, 2025	(20)	(20)	_	
Α	20	CAD	(110)	HKD	Apr. 9, 2025	(20)	(20)	_	
Α	18	CAD	(100)	HKD	Apr. 9, 2025	(18)	(18)	_	
Α	47	CAD	(260)	HKD	Apr. 9, 2025	(47)	(48)	_	
Α	90	HKD	(17)	CAD	Apr. 9, 2025	17	17	-	
Α	50	CAD	(270)	HKD	Apr. 9, 2025	(50)	(50)	_	
Α	120	HKD	(22)	CAD	Apr. 9, 2025	22	22	-	
Α	18	CAD	(100)	HKD	Apr. 9, 2025	(18)	(18)	-	
Α	130	HKD	(24)	CAD	Apr. 9, 2025	24	24	-	
Α	268	CAD	(150)	GBP	Apr. 11, 2025	(268)	(278)	_	(
Α	290	GBP	(527)	CAD	Apr. 11, 2025	527	541	14	
Α	270	GBP	(504)	CAD	Apr. 11, 2025	504	502	_	
Α	2,203	CAD	(2,476)	AUD	Apr. 16, 2025	(2,203)	(2,224)	_	(
Α	72	CAD	(80)	AUD	Apr. 16, 2025	(72)	(72)	_	
Α	151	AUD	(137)	CAD	Apr. 16, 2025	137	136	_	
Α	97	CAD	(108)	AUD	Apr. 16, 2025	(97)	(97)	_	
Α	2,882	CAD	(1,943)	EUR	Apr. 25, 2025	(2,882)	(3,024)	_	(1
Α	255	CAD	(170)	EUR	Apr. 25, 2025	(255)	(265)	=	(
Α	1,122	CAD	(5,620)	DKK	May 7, 2025	(1,122)	(1,173)	=	(
Α	342	CAD	(1,710)	DKK	May 7, 2025	(342)	(357)	=	(
Α	203	CAD	(1,000)	DKK	May 7, 2025	(203)	(209)	_	
Α	666	DKK	(140)	CAD	May 7, 2025	140	139	=	
Α	157	CAD	(745)	DKK	May 7, 2025	(157)	(155)	2	
Α	337	DKK	(70)	CAD	May 7, 2025	70	70	=	
Α	9,604	CAD	(5,393)	GBP	May 7, 2025	(9,604)	(10,008)	=	(4
Α	981	CAD	(7,410)	SEK	May 14, 2025	(981)	(1,061)	=	(
Α	398	SEK	(53)	CAD	May 14, 2025	53	57	4	
Α	290	SEK	(41)	CAD	May 14, 2025	41	41	_	
Α	240	SEK	(34)	CAD	May 14, 2025	34	34	_	
Α	166	CAD	(168,468)	KOR	May 16, 2025	(166)	(164)	2	
Α	13	CAD	(13,000)	KOR	May 16, 2025	(13)	(13)	_	
Α	12,820	KOR	(13)	CAD	May 16, 2025	13	13	_	
Α	10	CAD	(9,690)	KOR	May 16, 2025	(10)	(10)	_	
Α	13	CAD	(12,850)	KOR	May 16, 2025	(13)	(13)	=	
Α	5,990	KOR	(6)	CAD	May 16, 2025	6	6	=	
A	867	CAD	(19,979)	NTD	May 16, 2025	(867)	(867)	_	
A	1,540	NTD	(67)	CAD	May 16, 2025	67	67	_	
A	850	NTD	(37)	CAD	May 16, 2025	37	36	_	
A	520	NTD	(23)	CAD	May 16, 2025	23	23	=	
A	1,050	NTD	(45)	CAD	May 16, 2025	45	45	_	
A	960	CAD	(612)	EUR	Jun. 13, 2025	(960)	(953)	7	
A	60	EUR	(93)	CAD	Jun. 13, 2025	93	93	_	
I forward currency			(30)					32	(8
	,								,,,
l Derivative assets									
I Derivative liabiliti	es								(8

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

1. Fiscal Periods and General Information

The Fund is organized as an open-ended mutual fund trust established under the laws of the Province of Ontario pursuant to a Declaration of Trust as amended and restated from time to time. The address of the Fund's registered office is 180 Queen Street West, Toronto, Ontario, Canada. The Fund is authorized to issue an unlimited number of units (referred to as "security" or "securities") of multiple series. Series of the Fund are available for sale under Simplified Prospectus or exempt distribution options.

The information provided in these financial statements and notes thereto is for the periods ended or as at March 31, 2025 and 2024. In the year a Fund or series is established or reinstated, 'period' represents the period from inception or reinstatement. Where a series of a Fund was terminated during either period, the information for the series is provided up to close of business on the termination date. Refer to Note 10 (a) for the formation date of the Fund and the inception date of each series.

Mackenzie Financial Corporation ("Mackenzie") is the manager of the Fund and is wholly owned by IGM Financial Inc., a subsidiary of Power Corporation of Canada. Canada Life Investment Management Ltd. ("CLIML") is wholly owned by The Canada Life Assurance Company ("Canada Life"), a subsidiary of Power Corporation of Canada. Investments in companies within the Power Group of companies held by the Fund are identified in the Schedule of Investments.

2. Basis of Preparation and Presentation

These audited annual financial statements ("financial statements") have been prepared in accordance with IFRS Accounting Standards ("IFRS"). A summary of the Fund's material accounting policies under IFRS is presented in Note 3.

These financial statements are presented in Canadian dollars, which is the Fund's functional and presentation currency, and rounded to the nearest thousand unless otherwise indicated. These financial statements are prepared on a going concern basis using the historical cost basis, except for financial instruments that have been measured at fair value.

These financial statements were authorized for issue by the Board of Directors of Mackenzie on June 4, 2025.

3. Material Accounting Policies

(a) Financial instruments

Financial instruments include financial assets and liabilities such as debt and equity securities, investment funds and derivatives. The Fund classifies and measures financial instruments in accordance with IFRS 9, *Financial Instruments* ("IFRS 9"). Upon initial recognition, financial instruments are classified as fair value through profit or loss ("FVTPL"). All financial instruments are recognized in the Statement of Financial Position when the Fund becomes a party to the contractual requirements of the instrument. Financial assets are derecognized when the right to receive cash flows from the instrument has expired or the Fund has transferred substantially all risks and rewards of ownership. Financial liabilities are derecognized when the obligation is discharged, cancelled or expires. Investment purchase and sale transactions are recorded as of the trade date.

Financial instruments are subsequently measured at FVTPL with changes in fair value recognized in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The cost of investments is determined on a weighted average cost basis.

Realized and unrealized gains and losses on investments are calculated based on the weighted average cost of investments and exclude commissions and other portfolio transaction costs, which are separately reported in the Statement of Comprehensive Income – Commissions and other portfolio transaction costs.

Gains and losses arising from changes in the fair value of the investments are included in the Statement of Comprehensive Income for the period in which they arise.

The Fund accounts for its holdings in unlisted open-ended investment funds, private funds ("Underlying Funds") and Exchange-Traded Funds ("ETFs"), if any, at FVTPL. For private funds, Mackenzie will rely on the valuations provided by the managers of the private funds, which represents the Fund's proportionate share of the net assets of these private funds. The Fund's investment in Underlying Funds and ETFs, if any, is presented in the Schedule of Investments at fair value which represents the Fund's maximum exposure on these investments.

The Fund's redeemable securities contain multiple dissimilar contractual obligations and entitle securityholders to the right to redeem their interest in the Fund for cash equal to their proportionate share of the net asset value of the Fund and therefore meet the criteria for classification as financial liabilities under IAS 32, *Financial Instruments: Presentation.* The Fund's obligation for net assets attributable to securityholders is presented at the redemption amount.

IAS 7, Statement of Cash Flows, requires disclosures related to changes in liabilities and assets, such as the securities of the Fund, arising from financing activities. Changes in securities of the Fund, including both changes from cash flows and non-cash changes, are included in the Statement of Changes in Financial Position. Any changes in the securities not settled in cash as at the end of the period are presented as either Accounts receivable for securities issued or Accounts payable for securities redeemed in the Statement of Financial Position. These accounts receivable and accounts payable amounts typically settle shortly after period-end.

(b) Fair value measurement

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(b) Fair value measurement (cont'd)

Investments listed on a public securities exchange or traded on an over-the-counter market, including ETFs, are valued on the basis of the last traded market price or closing price recorded by the security exchange on which the security is principally traded, where this price falls within the quoted bid-ask spread for the investment. In circumstances where this price is not within the bid-ask spread, Mackenzie determines the point within the bid-ask spread that is most representative of fair value based on the specific facts and circumstances. Mutual fund securities of an underlying fund are valued on a business day at the price calculated by the manager of such underlying fund in accordance with the constating documents of such underlying fund. Unlisted or non-exchange traded investments, or investments where a last sale or close price is unavailable or investments for which market quotations are, in Mackenzie's opinion, inaccurate, unreliable, or not reflective of all available material information, are valued at their fair value as determined by Mackenzie using appropriate and accepted industry valuation techniques including valuation models. The fair value determined using valuation models requires the use of inputs and assumptions based on observable market data including volatility and other applicable rates or prices. In limited circumstances, the fair value may be determined using valuation techniques that are not supported by observable market data.

Cash and cash equivalents which includes cash on deposit with financial institutions and short-term investments that are readily convertible to cash, are subject to an insignificant risk of changes in value, and are used by the Fund in the management of short-term commitments. Cash and cash equivalents and short-term investments are reported at fair value which closely approximates their amortized cost due to their nature of being highly liquid and having short terms to maturity. Bank overdraft positions are presented under current liabilities as bank indebtedness in the Statement of Financial Position. Short-term investments that are not considered cash equivalents are separately disclosed in the Schedule of Investments.

The Fund may use derivatives (such as written options, futures, forward contracts, swaps or customized derivatives) to hedge against losses caused by changes in securities prices, interest rates or exchange rates. The Fund may also use derivatives for non-hedging purposes in order to invest indirectly in securities or financial markets, to gain exposure to other currencies, to seek to generate additional income, and/or for any other purpose considered appropriate by the Fund's portfolio manager(s), provided that the use of the derivative is consistent with the Fund's investment objectives. Any use of derivatives will comply with Canadian mutual fund laws, subject to the regulatory exemptions granted to the Fund, as applicable.

Valuations of derivative instruments are carried out daily, using normal exchange reporting sources for exchange-traded derivatives and specific broker enquiry for over-the-counter derivatives.

The value of forward contracts is the gain or loss that would be realized if, on the valuation date, the positions were to be closed out. The change in value of forward contracts is included in the Statement of Comprehensive Income — Other changes in fair value of investments and other net assets — Net unrealized gain (loss).

The daily fluctuation of futures contracts or swaps, along with daily cash settlements made by the Fund, where applicable, are equal to the change in unrealized gains or losses that are best determined at the settlement price. These unrealized gains or losses are recorded and reported as such until the Fund closes out the contract or the contract expires. Margin paid or deposited in respect of futures contracts or swaps is reflected as a receivable in the Statement of Financial Position — Margin on derivatives. Any change in the variation margin requirement is settled daily.

Premiums paid for purchasing an option are recorded in the Statement of Financial Position – Investments at fair value.

Premiums received from writing options are included in the Statement of Financial Position as a liability and subsequently adjusted daily to fair value. If a written option expires unexercised, the premium received is recognized as a realized gain. If a written call option is exercised, the difference between the proceeds of the sale plus the value of the premium, and the cost of the security is recognized as a realized gain or loss. If a written put option is exercised, the cost of the security acquired is the exercise price of the option less the premium received.

Refer to the Schedule of Derivative Instruments and Schedule of Options Purchased/Written, as applicable, included in the Schedule of Investments for a listing of derivative and options positions as at March 31, 2025.

The Fund categorizes the fair value of its assets and liabilities into three categories, which are differentiated based on the observable nature of the inputs and extent of estimation required.

Level 1- Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly. Examples of Level 2 valuations include quoted prices for similar securities, quoted prices on inactive markets and from recognized investment dealers, and the application of factors derived from observable data to non-North American quoted prices in order to estimate the impact of differences in market closing times.

Financial instruments classified as Level 2 investments are valued based on the prices provided by an independent reputable pricing services company who prices the securities based on recent transactions and quotes received from market participants and through incorporating observable market data and using standard market convention practices. Short-term investments classified as Level 2 investments are valued based on amortized cost plus accrued interest which closely approximates fair value.

The estimated fair values for these securities may be different from the values that would have been used had a ready market for the investment existed; and Level 3 – Inputs that are not based on observable market data.

The inputs are considered observable if they are developed using market data, such as publicly available information about actual events or transactions, and that reflect the assumption that market participants would use when pricing the asset or liability.

See Note 10 for the fair value classifications of the Fund.

(c) Income recognition

Interest income for distribution purposes represents the coupon interest received by the Fund which is accounted for on an accrual basis. The Fund does not amortize premiums paid or discounts received on the purchase of fixed income securities except for zero coupon bonds, which are amortized on a straight-line basis. Dividends are accrued as of the ex-dividend date. Unrealized gains or losses on investments, realized gains or losses on the sale of investments, including foreign exchange gains or losses on such investments, are calculated on a weighted average cost basis. Distributions received from an Underlying Fund or ETF are included in Interest income for distribution purposes, Dividends income, Net realized gain (loss) or Fee rebate income, as appropriate, on the ex-dividend or distribution date.

Income, realized gains (losses) and unrealized gains (losses) are allocated daily among the series on a pro-rata basis.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

3. Material Accounting Policies (cont'd)

(d) Commissions and other portfolio transaction costs

Commissions and other portfolio transaction costs are costs incurred to acquire, issue or dispose of financial assets or liabilities. They include fees and commissions paid to agents, exchanges, brokers, dealers and other intermediaries. The total brokerage commissions incurred by the Fund in connection with portfolio transactions for the periods, together with other transaction charges, is disclosed in the Statements of Comprehensive Income. Brokerage business is allocated to brokers based on the best net result for the Fund. Subject to this criteria, commissions may be paid to brokerage firms which provide (or pay for) certain services, other than order execution, which may include investment research, analysis and reports, and databases or software in support of these services. Where applicable and ascertainable, the value of these services generated during the periods is disclosed in Note 10. The value of certain proprietary services provided by brokers cannot be reasonably estimated.

(e) Securities lending, repurchase and reverse repurchase transactions

The Fund is permitted to enter into securities lending, repurchase and reverse repurchase transactions as set out in the Fund's Simplified Prospectus. These transactions involve the temporary exchange of securities for collateral with a commitment to redeliver the same securities on a future date.

Income is earned from these transactions in the form of fees paid by the counterparty and, in certain circumstances, interest paid on cash or securities held as collateral. Income earned from these transactions is included in the Statement of Comprehensive Income and recognized when earned. Securities lending transactions are administered by The Bank of New York Mellon (the "Securities Lending Agent"). The value of cash or securities held as collateral must be at least 102% of the fair value of the securities loaned, sold or purchased.

Note 10 summarizes the details of securities loaned and collateral received as at the end of period, as well as a reconciliation of securities lending income during the period, if applicable. Collateral received is comprised of debt obligations of the Government of Canada and other countries, Canadian provincial and municipal governments, and financial institutions.

(f) Offsetting

Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position only when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or to realize the asset and settle the liability simultaneously. In the normal course of business, the Fund enters into various master netting agreements or similar agreements that do not meet the criteria for offsetting in the Statement of Financial Position but still allow for the related amounts to be set off in certain circumstances, such as bankruptcy or termination of the contracts. Note 10 summarizes the details of such offsetting, if applicable, subject to master netting arrangements or other similar agreements and the net impact to the Statements of Financial Position if all such rights were exercised.

Income and expenses are not offset in the Statement of Comprehensive Income unless required or permitted to by an accounting standard, as specifically disclosed in the IFRS policies of the Fund.

(g) Currency

The functional and presentation currency of the Fund is Canadian dollars. Foreign currency purchases and sales of investments and foreign currency dividend and interest income and expenses are translated to Canadian dollars at the rate of exchange prevailing at the time of the transactions.

Foreign exchange gains (losses) on purchases and sales of foreign currencies are included in the Statement of Comprehensive Income – Other changes in fair value of investments and other net assets – Net realized gain (loss).

The fair value of investments and other assets and liabilities, denominated in foreign currencies, are translated to Canadian dollars at the rate of exchange prevailing on each business day.

(h) Net assets attributable to securityholders per security

Net assets attributable to securityholders per security is computed by dividing the net assets attributable to securityholders of a series of securities on a business day by the total number of securities of the series outstanding on that day.

(i) Net asset value per security

The daily Net Asset Value ("NAV") of an investment fund may be calculated without reference to IFRS as per the Canadian Securities Administrators' ("CSA") regulations. The difference between NAV and Net assets attributable to securityholders (as reported in the financial statements), if any, is mainly due to differences in fair value of investments and other financial assets and liabilities and is disclosed in Note 10, if applicable.

(j) Increase (decrease) in net assets attributable to securityholders from operations per security

Increase (decrease) in net assets attributable to securityholders from operations per security in the Statement of Comprehensive Income represents the increase (decrease) in net assets attributable to securityholders from operations for the period, divided by the weighted average number of securities outstanding during the period.

(k) Mergers

In a fund merger, the Fund acquires all of the assets and assumes all of the liabilities of the terminating fund at fair value in exchange for securities of the Fund on the effective date of the merger.

(I) Future accounting changes

In April 2024, the International Accounting Standards Board ("IASB") issued IFRS 18, *Presentation and Disclosure in Financial Statements* ("IFRS 18"). IFRS 18, which replaces IAS 1, *Presentation of financial statements*, introduces new requirements to present specified categories and defined subtotals in the statement of comprehensive income, new disclosure for management-defined performance measures, and additional requirements for aggregation and disaggregation of information.

The standard is effective for annual reporting periods beginning on or after January 1, 2027, with earlier application permitted. Mackenzie is assessing the impact of the adoption of this standard.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

4. Critical Accounting Estimates and Judgments

The preparation of these financial statements requires management to make estimates and assumptions that primarily affect the valuation of investments. Estimates and assumptions are reviewed on an ongoing basis. Actual results may differ from these estimates.

The following discusses the most significant accounting judgments and estimates made in preparing the financial statements:

Use of Estimates

Fair value of securities not quoted in an active market

The Fund may hold financial instruments that are not quoted in active markets and are valued using valuation techniques that make use of observable data, to the extent practicable. Various valuation techniques are utilized, depending on a number of factors, including comparison with similar instruments for which observable market prices exist and recent arm's length market transactions. Key inputs and assumptions used are company specific and may include estimated discount rates and expected price volatilities. Changes in key inputs, could affect the reported fair value of these financial instruments held by the Fund.

Use of Judgments

Classification and measurement of investments

In classifying and measuring financial instruments held by the Fund, Mackenzie is required to make significant judgments in order to determine the most appropriate classification in accordance with IFRS 9. Mackenzie has assessed the Fund's business model, the manner in which all financial instruments are managed and performance evaluated as a group on a fair value basis, and concluded that FVTPL in accordance with IFRS 9 provides the most appropriate measurement and presentation of the Fund's financial instruments.

Functional currency

The Fund's functional and presentation currency is the Canadian dollar, which is the currency considered to best represent the economic effects of the Fund's underlying transactions, events and conditions taking into consideration the manner in which securities are issued and redeemed and how returns and performance by the Fund are measured.

Interest in unconsolidated structured entities

In determining whether an Underlying Fund or an ETF in which the Fund invests, but that it does not consolidate, meets the definition of a structured entity, Mackenzie is required to make significant judgments about whether these underlying funds have the typical characteristics of a structured entity. These Underlying Funds do meet the definition of a structured entity because:

- I. The voting rights in the Underlying Funds are not dominant factors in deciding who controls them;
- II. the activities of the Underlying Funds are restricted by their offering documents; and
- III. the Underlying Funds have narrow and well-defined investment objectives to provide investment opportunities for investors while passing on the associated risks and rewards.

As a result, such investments are accounted for at FVTPL. Note 10 summarizes the details of the Fund's interest in these Underlying Funds, if applicable.

5. Income Taxes

The Fund qualifies as a mutual fund trust under the provisions of the Income Tax Act (Canada) and, accordingly, is subject to tax on its income including net realized capital gains in the taxation year, which is not paid or payable to its securityholders as at the end of the taxation year. The Fund maintains a December year-end for tax purposes. The Fund may be subject to withholding taxes on foreign income. In general, the Fund treats withholding tax as a charge against income for tax purposes. The Fund will distribute sufficient amounts from net income for tax purposes, as required, so that the Fund will not pay income taxes other than refundable tax on capital gains. if applicable.

Losses of the Fund cannot be allocated to investors and are retained in the Fund for use in future years. Non-capital losses may be carried forward up to 20 years to reduce taxable income and realized capital gains of future years. Capital losses may be carried forward indefinitely to reduce future realized capital gains. Refer to Note 10 for the Fund's loss carryforwards.

6. Management Fees and Operating Expenses

Mackenzie is paid a management fee for managing the investment portfolio, providing investment analysis and recommendations, making investment decisions, making brokerage arrangements relating to the purchase and sale of the investment portfolio and making arrangements with registered dealers for the purchase and sale of securities of the Fund by investors. The management fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Each series of the Fund, except B-Series, is charged a fixed rate annual administration fee ("Administration Fee") and in return, Mackenzie bears all of the operating expenses of the Fund, other than certain specified fund costs. The Administration Fee is calculated on each series of securities of the Fund as a fixed annual percentage of the daily net asset value of the series.

Other fund costs include taxes (including, but not limited to GST/HST and income tax), interest and borrowing costs, all fees and expenses of the Mackenzie Funds' Independent Review Committee ("IRC"), costs of complying with the regulatory requirement to produce Fund Facts, fees paid to external service providers associated with tax reclaims, refunds or the preparation of foreign tax reports on behalf of the Funds, new fees related to external services that were not commonly charged in the Canadian mutual fund industry and introduced after the date of the most recently filed simplified prospectus, and the costs of complying with any new regulatory requirements, including, without limitation, any new fees introduced after the date of the most recently filed simplified prospectus.

All expenses relating to the operation of the Fund attributable to B-Series securities will be charged to that particular series. Operating expenses include legal, audit, transfer agent, custodian, administration and trustee services, cost of financial reporting and Simplified Prospectus printing, regulatory filing fees and other miscellaneous expenses specifically attributable to the B-Series securities and any applicable taxes.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

6. Management Fees and Operating Expenses (cont'd)

Mackenzie may waive or absorb management fees and/or Administration Fees at its discretion and stop waiving or absorbing such fees at any time without notice. Refer to Note 10 for the management fee and Administration Fee rates charged to each series of securities.

7. Fund's Capital

The capital of the Fund, which is comprised of the net assets attributable to securityholders, is divided into different series with each series having an unlimited number of securities. The securities outstanding for the Fund as at March 31, 2025 and 2024 and securities issued, reinvested and redeemed for the periods are presented in the Statement of Changes in Financial Position. Mackenzie manages the capital of the Fund in accordance with the investment objectives as discussed in Note 10.

8. Financial Instruments Risk

(a) Risk exposure and management

The Fund's investment activities expose it to a variety of financial risks, as defined in IFRS 7, *Financial Instruments: Disclosures* ("IFRS 7"). The Fund's exposure to financial risks is concentrated in its investments, which are presented in the Schedule of Investments, as at March 31, 2025, grouped by asset type, with geographic and sector information.

Mackenzie seeks to minimize potential adverse effects of financial risks on the Fund's performance by employing professional, experienced portfolio advisors, by monitoring the Fund's positions and market events daily, by diversifying the investment portfolio within the constraints of the Fund's investment objectives, and where applicable, by using derivatives to hedge certain risk exposures. To assist in managing risks, Mackenzie also maintains a governance structure that oversees the Fund's investment activities and monitors compliance with the Fund's stated investment strategy, internal guidelines, and securities regulations.

(b) Liquidity risk

Liquidity risk arises when the Fund encounters difficulty in meeting its financial obligations as they become due. The Fund is exposed to liquidity risk due to potential daily cash redemptions of redeemable securities. In order to monitor the liquidity of its assets, the Fund utilizes a liquidity risk management program that calculates the number of days to convert the investments held by the Fund into cash using a multi-day liquidation approach. This liquidity risk analysis assesses the Fund's liquidity against predetermined minimum liquidity percentages established for different time periods and is monitored quarterly. In addition, the Fund has the ability to borrow up to 5% of its net assets for the purposes of funding redemptions.

In order to comply with securities regulations, the Fund must maintain at least 85% of its assets in liquid investments (i.e., investments that can be readily sold).

(c) Currency risk

Currency risk is the risk that financial instruments which are denominated or exchanged in a currency other than the Canadian dollar, which is the Fund's functional currency, will fluctuate due to changes in exchange rates. Generally, foreign denominated investments increase in value when the value of the Canadian dollar (relative to foreign currencies) falls. Conversely, when the value of the Canadian dollar rises relative to foreign currencies, the values of foreign denominated investments fall.

Note 10 indicates the foreign currencies, if applicable, to which the Fund had significant exposure, including both monetary and non-monetary financial instruments, and illustrates the potential impact, in Canadian dollar terms, to the Fund's net assets had the Canadian dollar strengthened or weakened by 5% relative to all foreign currencies, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to currency risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts including forward currency contracts. Other financial assets and liabilities (including dividends and interest receivable, and receivables/payables for investments sold/purchased) that are denominated in foreign currencies do not expose the Fund to significant currency risk.

(d) Interest rate risk

Interest rate risk arises on interest-bearing financial instruments. The Fund is exposed to the risk that the value of interest-bearing financial instruments will fluctuate due to changes in the prevailing levels of market interest rates. Generally, these securities increase in value when interest rates fall and decrease in value when interest rates rise

If significant, Note 10 summarizes the Fund's interest-bearing financial instruments by remaining term to maturity and illustrates the potential impact to the Fund's net assets had prevailing interest rates increased or decreased by 1%, assuming a parallel shift in the yield curve, all other variables held constant. The Fund's sensitivity to interest rate changes was estimated using weighted average duration. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to interest rate risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts. Cash and cash equivalents and other money market instruments are short term in nature and are not generally subject to significant amounts of interest rate risk.

(e) Other price risk

Other price risk is the risk that the value of financial instruments will fluctuate as a result of changes in market prices (other than those arising from interest rate risk or currency risk), whether caused by factors specific to an individual investment, its issuer, or all factors affecting all instruments traded in a market or market segment. All investments present a risk of loss of capital. This risk is managed through a careful selection of investments and other financial instruments within the parameters of the investment strategies. Except for certain derivative contracts, the maximum risk resulting from financial instruments is equivalent to their fair value. The maximum risk of loss on certain derivative contracts such as forwards, swaps, and futures contracts is equal to their notional values. In the case of written call (put) options and short futures contracts, the loss to the Fund continues to increase, theoretically without limit, as the fair value of the underlying interest increases (decreases). However, these instruments are generally used within the overall investment management process to manage the risk from the underlying investments and do not typically increase the overall risk of loss to the Fund. This risk is mitigated by ensuring that the Fund holds a combination of the underlying interest, cash cover and/or margin that is equal to or greater than the value of the derivative contract.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

8. Financial Instruments Risk (cont'd)

(e) Other price risk (cont'd)

Other price risk typically arises from exposure to equity and commodity securities. If significant, Note 10 illustrates the potential increase or decrease in the Fund's net assets, had the prices on the respective exchanges for these securities increased or decreased by 10%, all other variables held constant. In practice, the actual trading results may differ and the difference could be material.

The Fund's sensitivity to other price risk illustrated in Note 10 includes potential indirect impacts from underlying funds and ETFs in which the Fund invests, and/or derivative contracts.

(f) Credit risk

Credit risk is the risk that a counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Fund. Note 10 summarizes the Fund's exposure, if applicable and significant, to credit risk.

If presented, credit ratings and rating categories are based on ratings issued by a designated rating organization. Indirect exposure to credit risk may arise from fixed-income securities, such as bonds, held by underlying funds and ETFs, if any. The fair value of debt securities includes consideration of the creditworthiness of the debt issuer.

To minimize the possibility of settlement default, securities are exchanged for payment simultaneously, where market practices permit, through the facilities of a central depository and/or clearing agency where customary.

The carrying amount of investments and other assets represents the maximum credit risk exposure as at the date of the Statement of Financial Position. The Fund may enter into securities lending transactions with counterparties and it may also be exposed to credit risk from the counterparties to the derivative instruments it may use. Credit risk associated with these transactions is considered minimal as all counterparties have a rating equivalent to a designated rating organization's credit rating of not less than A-1 (low) on their short-term debt and of A on their long-term debt, as applicable.

(g) Underlying funds

The Fund may invest in underlying funds and may be indirectly exposed to currency risk, interest rate risk, other price risk and credit risk from fluctuations in the value of financial instruments held by the underlying funds. Note 10 summarizes the Fund's exposure, if applicable and significant, to these risks from underlying funds.

9. Other Information

Abbreviations

HKD

Hong Kong dollars

Foreign currencies, if any, are presented in these financial statements using the following abbreviated currency codes:

PKR

Currency Code	Description	Currency Code	Description	Currency Code	Description
AUD	Australian dollars	HUF	Hungarian forint	PLN	Polish zloty
AED	United Arab Emirates Dirham	IDR	Indonesian rupiah	QAR	Qatar Rial
BRL	Brazilian real	ILS	Israeli shekel	RON	Romanian leu
CAD	Canadian dollars	INR	Indian rupee	RUB	Russian ruble
CHF	Swiss franc	JPY	Japanese yen	SAR	Saudi riyal
CZK	Czech koruna	KOR	South Korean won	SEK	Swedish krona
CLP	Chilean peso	MXN	Mexican peso	SGD	Singapore dollars
CNY	Chinese yuan	MYR	Malaysian ringgit	ТНВ	Thailand baht
СОР	Colombian peso	NGN	Nigerian naira	TRL	Turkish lira
DKK	Danish krone	NOK	Norwegian krona	USD	United States dollars
EGP	Egyptian pound	NTD	New Taiwan dollar	VND	Vietnamese dong
EUR	Euro	NZD	New Zealand dollars	ZAR	South African rand
GBP	United Kingdom pounds	PEN	Peruvian nuevo sol	ZMW	Zambian kwacha
GHS	Ghana Cedi	PHP	Philippine peso		

Pakistani rupee

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a))

(a) Fund Formation and Series Information

Date of Formation: October 9, 1985

The Fund may issue an unlimited number of securities of each series. The number of issued and outstanding securities of each series is disclosed in the Statements of Changes in Financial Position.

Series Offered by Mackenzie Financial Corporation (180 Queen Street West, Toronto, Ontario, M5V 3K1; 1-800-387-0614; www.mackenzieinvestments.com)

Series A, Series T5 and Series T8 securities are offered to retail investors investing a minimum of \$500 (\$5,000 for Series T5 and Series T8). Investors in Series T5 and Series T8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series AR securities are offered to retail investors in a Registered Disability Savings Plan offered by Mackenzie.

Series D securities are offered to retail investors investing a minimum of \$500 through a discount brokerage or other account approved by Mackenzie.

Series F, Series F5 and Series F8 securities are offered to retail investors who are enrolled in a dealer-sponsored fee-for-service or wrap program, who are subject to an asset-based fee rather than commissions on each transaction and who invest at least \$500 (\$5,000 for Series F5 and Series F8); they are also available to employees of Mackenzie and its subsidiaries, and directors of Mackenzie. Investors in Series F5 and Series F8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series FB and Series FB5 securities are offered to retail investors investing a minimum of \$500. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series FB5 securities also want to receive a monthly cash flow of 5% per year.

Series I securities are offered to retail investors investing a minimum of \$500 in a qualified group plan with a minimum of \$10,000,000 in assets.

Series O securities are offered only to investors investing a minimum of \$500,000 who are enrolled in Mackenzie Portfolio Architecture Service or Open Architecture Service; retail investors investing a minimum of \$5 million, certain institutional investors; investors in a qualified group plan, and certain qualifying employees of Mackenzie and its subsidiaries.

Series PW, Series PWT5 and Series PWT8 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors in Series PWT5 and Series PWT8 securities also want to receive a monthly cash flow of 5% or 8% per year, respectively.

Series PWFB and Series PWFB5 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series PWFB5 securities also want to receive a monthly cash flow of 5% per year.

Series PWR securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000 in a Registered Disability Savings Plan offered by Mackenzie.

Series PWX and Series PWX8 securities are offered through our Private Wealth Solutions to certain high net worth investors who invest a minimum of \$100,000. Investors are required to negotiate their advisor service fee, which cannot exceed 1.50%, with their financial advisor. Investors in Series PWX8 securities also want to receive a monthly cash flow of 8% per year.

Series R securities are offered only to other funds managed by Mackenzie on a non-prospectus basis in connection with fund-of-fund arrangements.

Series S securities are offered to The Canada Life Assurance Company and certain other mutual funds, but may be sold to other investors as determined by Mackenzie.

Series Distributed by LBC Financial Services Inc. (1360 René-Lévesque Blvd. West, 13th Floor, Montréal, Québec H3G 0A9; 1-800-522-1846; www.laurentianbank.ca/mackenzie)

Series LB and Series LW securities are no longer available for sale, except for additional purchases by investors who have held these securities since December 11, 2017.

Series LF securities were created specifically for the purpose of implementing mergers affecting the Fund and are not available for sale except for additional purchases by investors who have held these securities since November 25, 2021.

Effective June 1, 2022, an investor may purchase the Fund under a sales charge purchase option and a no-load purchase option. Not all purchase options are available under each series of the Fund. The sales charge under the sales charge purchase option is negotiated by the investor with their dealer. Securities purchased before June 1, 2022, under the redemption charge purchase option and low-load 3 purchase option (collectively the "deferred sales charge purchase options") may continue to be held in investor accounts. Investors may switch from securities of a Mackenzie fund previously purchased under these deferred sales charge purchase options to securities of other Mackenzie funds, under the same purchase option, until such time as the redemption schedule has expired. For further details, please refer to the Fund's Simplified Prospectus and Fund Facts.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (a) Fund Formation and Series Information (cont'd)

Series A October 9, 1985 2.00% 0.25% Series AR July 6, 2018 2.00% 0.31% Series D March 19, 2014 1.00% 0.20% Series F December 6, 1999 0.80% 0.15% Series F5 July 6, 2018 0.80% 0.15% Series F8 October 24, 2018 0.80% 0.15% Series FB October 26, 2015 1.00% 0.28% Series I October 24, 2018 1.00% 0.28% Series I October 25, 1999 1.35% 0.28% Series O June 28, 2000 -(1) n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX F	Series	Inception/ Reinstatement Date	Management Fee	Administration Fee
Series D March 19, 2014 1.00% 0.20% Series F December 6, 1999 0.80% 0.15% Series F5 July 6, 2018 0.80% 0.15% Series F8 October 24, 2018 0.80% 0.15% Series FB October 26, 2015 1.00% 0.28% Series FB5 October 24, 2018 1.00% 0.28% Series I October 25, 1999 1.35% 0.28% Series O June 28, 2000 -(1) n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 - (2) - (2) Series PWX February 28, 2005 - (2) - (2) Series TS	Series A		<u> </u>	
Series F December 6, 1999 0.80% 0.15% Series F5 July 6, 2018 0.80% 0.15% Series F8 October 24, 2018 0.80% 0.15% Series FB October 26, 2015 1.00% 0.28% Series FB5 October 24, 2018 1.00% 0.28% Series I October 25, 1999 1.35% 0.28% Series O June 28, 2000 -(1) n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX February 28, 2005 -(1) 0.03% Series S February 28, 2005 -(1) 0.03% Series T5	Series AR	July 6, 2018	2.00%	0.31%
Series F5 July 6, 2018 0.80% 0.15% Series F8 October 24, 2018 0.80% 0.15% Series FB October 26, 2015 1.00% 0.28% Series FB5 October 24, 2018 1.00% 0.28% Series I October 25, 1999 1.35% 0.28% Series O June 28, 2000 -00 n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWRB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 <t< td=""><td>Series D</td><td>March 19, 2014</td><td>1.00%</td><td>0.20%</td></t<>	Series D	March 19, 2014	1.00%	0.20%
Series F8 October 24, 2018 0.80% 0.15% Series FB October 26, 2015 1.00% 0.28% Series FB5 October 24, 2018 1.00% 0.28% Series I October 25, 1999 1.35% 0.28% Series O June 28, 2000 -01 n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5	Series F	December 6, 1999	0.80%	0.15%
Series FB October 26, 2015 1.00% 0.28% Series FB5 October 24, 2018 1.00% 0.28% Series I October 25, 1999 1.35% 0.28% Series O June 28, 2000 -(1) n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX February 28, 2018 -(2) -(2) Series PWX October 24, 2018 -(2) -(2) Series TS July 6, 2018 2.00% 0.28% Series TS July 6, 2018 2.00% 0.28% Series TB October 24, 2018 2.00% 0.28% Series TB	Series F5	July 6, 2018	0.80%	0.15%
Series FB5 October 24, 2018 1.00% 0.28% Series I October 25, 1999 1.35% 0.28% Series O June 28, 2000 -(1) n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.25%(3)	Series F8	October 24, 2018	0.80%	0.15%
Series I October 25, 1999 1.35% 0.28% Series O June 28, 2000 -(1) n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25% (3)	Series FB	October 26, 2015	1.00%	0.28%
Series O June 28, 2000 -(1) n/a Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25% (3)	Series FB5	October 24, 2018	1.00%	0.28%
Series PW November 14, 2013 1.80% 0.15% Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series I	October 25, 1999	1.35%	0.28%
Series PWFB April 3, 2017 0.80% 0.15% Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWX8 October 24, 2018 1.80% 0.15% Series PWX8 February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series 0	June 28, 2000	_(1)	n/a
Series PWFB5 October 24, 2018 0.80% 0.15% Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series PW	November 14, 2013	1.80%	0.15%
Series PWR April 1, 2019 1.80% 0.15% Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 - (2) - (2) Series PWX8 October 24, 2018 - (2) - (2) Series R None Issued (3) n/a n/a Series S February 28, 2005 - (1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series PWFB	April 3, 2017	0.80%	0.15%
Series PWT5 July 6, 2018 1.80% 0.15% Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series PWFB5	October 24, 2018	0.80%	0.15%
Series PWT8 October 24, 2018 1.80% 0.15% Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series PWR	April 1, 2019	1.80%	0.15%
Series PWX February 18, 2014 -(2) -(2) Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series PWT5	July 6, 2018	1.80%	0.15%
Series PWX8 October 24, 2018 -(2) -(2) Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series PWT8	October 24, 2018	1.80%	0.15%
Series R None Issued (3) n/a n/a Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series PWX	February 18, 2014	_(2)	_(2)
Series S February 28, 2005 -(1) 0.03% Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series PWX8	October 24, 2018	_(2)	_(2)
Series T5 July 6, 2018 2.00% 0.28% Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series R	None Issued (3)	n/a	n/a
Series T8 October 24, 2018 2.00% 0.28% Series LB December 9, 2014 2.00% 0.25%(3)	Series S	February 28, 2005	_(1)	0.03%
Series LB December 9, 2014 2.00% 0.25%(3)	Series T5	July 6, 2018	2.00%	0.28%
·	Series T8	October 24, 2018	2.00%	0.28%
Series LF December 16, 2021 0.80% 0.15%	Series LB	December 9, 2014	2.00%	0.25%(3)
	Series LF	December 16, 2021	0.80%	0.15%

⁽¹⁾ This fee is negotiable and payable directly to Mackenzie by investors in this series.

December 1, 2017

(b) Tax Loss Carryforwards

Series LW

Expiration Date of Non-Capital Losses

1.80%

0.15%

Total	Total														
Capital	Non-Capital	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044
Loss \$	Loss \$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$
91,080	_	l _	_	_	_	_	_	_	_	_	_		_	_	

(c) Securities Lending

	March 31, 2025	March 31, 2024
	(\$)	(\$)
Value of securities loaned	2,071	_
Value of collateral received	2,228	_

⁽²⁾ This fee is payable directly to Mackenzie by investors in this series through redemptions of their securities.

⁽³⁾ The series' original start date was December 14, 2022. All securities in the series were redeemed on April 16, 2024.

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

10. Fund Specific Information (in '000, except for (a)) (cont'd)

(c) Securities Lending (cont'd)

	March	31, 2025	March 31, 2024		
	(\$)	(%)	(\$)	(%)	
Gross securities lending income	6	100.0	6	100.0	
Tax withheld	_	-	-	-	
	6	100.0	6	100.0	
Payments to securities lending agent	(1)	(16.7)	(1)	(16.7)	
Securities lending income	5	83.3	5	83.3	

(d) Commissions

	(\$)
March 31, 2025	25
March 31, 2024	26

(e) Risks Associated with Financial Instruments

i. Risk exposure and management

The Fund seeks long-term capital growth, while trying to preserve its capital, by investing primarily in equities of companies located in the following three principal market regions: (i) Europe and the United Kingdom; (ii) Australia and New Zealand; and (iii) Asia and the Far East.

ii. Currency risk

The tables below summarize the Fund's exposure to currency risk.

			Marc	h 31, 2025				
-				-		Impact on	net assets	
Currency	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure* (\$)	Strengthene	d by 5% (%)	Weakened	l by 5 %
JPY	13,284	797	_	14,081				
EUR	13,860	425	(4,149)	10,136				
GBP	18,477	_	(9,243)	9,234				
CHF	5,423	640	(3,872)	2,191				
DKK	3,397	(10)	(1,685)	1,702				
KOR	1,764	_	(181)	1,583				
AUD	3,726	84	(2,257)	1,553				
SEK	2,347	_	(929)	1,418				
HKD	990	576	(407)	1,159				
NTD	1,409	_	(696)	713				
USD	_	4	_	4				
Total	64,677	2,516	(23,419)	43,774				
% of Net Assets	91.6	3.6	(33.2)	62.0				
Total currency rate sensitivit	у				(2,189)	(3.1)	2,189	3.1

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (e) Risks Associated with Financial Instruments (cont'd)

ii. Currency risk (cont'd)

March 31, 2024

						Impact on	net assets	
Currency	Investments (\$)	Cash and Short-Term Investments (\$)	Derivative Instruments (\$)	Net Exposure* (\$)	Strengthene	ed by 5% (%)	Weakened	d by 5% (%)
JPY	12,107	443	_	12,550				
GBP	17,818	355	(9,265)	8,908				
EUR	10,951	576	(3,355)	8,172				
AUD	5,031	53	(2,881)	2,203				
KOR	1,885	_	(183)	1,702				
DKK	4,173	_	(2,479)	1,694				
CHF	7,351	207	(5,988)	1,570				
SEK	1,557	_	_	1,557				
HKD	1,260	572	(508)	1,324				
NTD	1,994	_	(1,003)	991				
USD	_	5	_	5				
Total	64,127	2,211	(25,662)	40,676				
% of Net Assets	89.9	3.1	(36.0)	57.0				
Total currency rate sensitivit	ty				(2,034)	(2.9)	2,034	2.9

^{*} Includes both monetary and non-monetary financial instruments

As at March 31, 2025 and 2024, the Fund did not have a significant exposure to interest rate risk.

iv. Other price risk

The table below summarizes the Fund's exposure to other price risk.

	Increased by	10%	Decreased by 10%		
Impact on net assets	(\$)	(%)	(\$)	(%)	
March 31, 2025	6,818	9.7	(6,818)	(9.7)	
March 31, 2024	6,753	9.5	(6,753)	(9.5)	

v. Credit risk

As at March 31, 2025 and 2024, the Fund did not have a significant exposure to credit risk.

(f) Fair Value Classification

The table below summarizes the fair value of the Fund's financial instruments using the fair value hierarchy described in note 3.

		March 31, 2025				March 31, 2024				
	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)	Level 1 (\$)	Level 2 (\$)	Level 3 (\$)	Total (\$)		
Equities	3,499	64,677	_	68,176	67,530	_	_	67,530		
Derivative assets	_	32	_	32	_	411	-	411		
Derivative liabilities	_	(858)	_	(858)	_	(62)	-	(62)		
Total	3,499	63,851	_	67,350	67,530	349	_	67,879		

The Fund's policy is to recognize transfers into and transfers out of fair value hierarchy levels as of the date of the event or change in circumstances that caused the transfer.

During the period ended March 31, 2025, non-North American equities frequently transferred between Level 1 (unadjusted quoted market prices) and Level 2 (adjusted market prices). As at March 31, 2025, these securities were classified as Level 2 (2024 – Level 1).

iii. Interest rate risk

ANNUAL AUDITED FINANCIAL STATEMENTS | March 31, 2025

NOTES TO FINANCIAL STATEMENTS

- 10. Fund Specific Information (in '000, except for (a)) (cont'd)
- (g) Investments by the Manager and Affiliates

The investments held by the Manager, other funds managed by the Manager, and funds managed by affiliates of the Manager, investing in series CL, IG or S of the Fund, as applicable (as described in *Fund Formation and Series Information* in note 10), were as follows:

	March 31, 2025	March 31, 2024	
	(\$)	(\$)	
The Manager	27	24	
Other funds managed by the Manager	_	129	
Funds managed by affiliates of the Manager	34,512	33,628	

(h) Offsetting of Financial Assets and Liabilities

The tables below present financial assets and financial liabilities that are subject to master netting arrangements or other similar agreements and the net impact on the Fund's Statements of Financial Position if all set-off rights were exercised as part of future events such as bankruptcy or termination of contracts. No amounts were offset in the financial statements.

	March 31, 2025			
	Gross amount of assets/liabilities (\$)	Amount available for offset (\$)	Margin (\$)	Net amount (\$)
Unrealized gains on derivative contracts	18	(18)	-	-
Unrealized losses on derivative contracts	(440)	18	-	(422)
Liability for options written	_	-	-	_
Total	(422)	_	-	(422)

	March 31, 2024				
	Gross amount of assets/liabilities (\$)	Amount available for offset (\$)	Margin (\$)	Net amount (\$)	
Unrealized gains on derivative contracts	389	(16)	-	373	
Unrealized losses on derivative contracts	(22)	16	_	(6)	
Liability for options written	-	-	-	_	
Total	367	-	-	367	

(i) Interest in Unconsolidated Structured Entities

As at March 31, 2025 and 2024, the Fund had no investments in Underlying Funds.